cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1209Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕМесто нитратов в современной кардиологииNitrate place in modern cardiologyЗатейщиковД. А.ZateyshchikovD. A.dz@bk.ruДанковцеваЕ. Н.DankovtsevaE. N.dz@bk.ruУчебно-научный медицинский центр Управления делами Президента РФ, МоскваTraining and Research Medical Center, Russian Federation President's Administration, Moscow200720042007628084Copyright © Затейщиков Д.А., Данковцева Е.Н., 20072007Затейщиков Д.А., Данковцева Е.Н.Zateyshchikov D.A., Dankovtseva E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1209

Рассматриваются механизмы терапевтического действия нитратов и их применение в кардиологической практике. Обсуждаются эффекты нитратов, приводятся клинические данные и современные рекомендации по их назначению при стенокардии, остром инфаркте миокарда, сердечной недостаточности, артериальной гипертензии. Большое внимание уделено механизмам развития толерантности к нитратам и методам борьбы с этим негативным явлением. Современные ретардные формы, в т.ч. изосорбида динитрата, имеют ряд преимуществ: в первую очередь существенно меньшую вероятность развития толерантности и отсутствие синдрома «рикошета» после отмены.

The authors review therapeutic action mechanisms of nitrates and their use in cardiology practice. Nitrate effects are discussed, clinical data and modern recommendations on nitrate treatment in angina, acute myocardial infarction, heart failure, and arterial hypertension are presented. Nitrate tolerance mechanisms and their prevention are emphasized. Modern retard forms, isosorbide dinitrate, in particular, have some benefits, e.g., lower chances of tolerance development and withdrawal syndrome.

ишемическая болезнь сердцасердечная недостаточностьартериальная гипертензиянитратыизосорбида динитратcoronary heart diseaseheart failurearterial hypertensionnitratesisosorbide dinitrateReferencesElkayam U. Organic nitrates – mechanisms of action and potencial limitations. Nitroglycerin 8: basics, standard and elective applications / Eight Hamburg Symposium. Ed. H.C. Mehmel. Berlin; New York: de Gruyter 1996; 75-87.Elkayam U. Organic nitrates – mechanisms of action and potencial limitations. Nitroglycerin 8: basics, standard and elective applications / Eight Hamburg Symposium. Ed. H.C. Mehmel. Berlin; New York: de Gruyter 1996; 75-87.Wlazlowski R, Kruszynski G, Goch JH. Effects of nitrates and beta-blockers on platelet aggregation in patients with coronary heart disease. Pol Merkuriusz Lek 2000; 8(44): 77-9.Wlazlowski R, Kruszynski G, Goch JH. Effects of nitrates and beta-blockers on platelet aggregation in patients with coronary heart disease. Pol Merkuriusz Lek 2000; 8(44): 77-9.Лупанов В. П., Алексеева И. А., Васильева Н. Н. и др. Сpавнительное изучение изосоpбида ди- и мононитpатов у больных ишемической болезнью сеpдца со стабильной стенокаpдией, обусловленной стенозиpующим коpонаpным атеpосклеpозом. Клин мед 2000; 78(9): 52-5.Лупанов В. П., Алексеева И. А., Васильева Н. Н. и др. Сpавнительное изучение изосоpбида ди- и мононитpатов у больных ишемической болезнью сеpдца со стабильной стенокаpдией, обусловленной стенозиpующим коpонаpным атеpосклеpозом. Клин мед 2000; 78(9): 52-5.Преображенский Д.В., Сидоренко Б.А., Ревунова И.В. Ангиоспастическая стенокардия: диагностика, течение и медикаментозная терапия. РМЖ 1998; 6(14): 880-6.Преображенский Д.В., Сидоренко Б.А., Ревунова И.В. Ангиоспастическая стенокардия: диагностика, течение и медикаментозная терапия. РМЖ 1998; 6(14): 880-6.Lip GYH, Lydakis C, Beevers DG. Management of patients with myocardial infarction and hypertension. European Heart Journal 2000; 21(14): 1125-34.Lip GYH, Lydakis C, Beevers DG. Management of patients with myocardial infarction and hypertension. European Heart Journal 2000; 21(14): 1125-34.ISIS44: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345(8951): 669-85.ISIS44: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345(8951): 669-85.Littrell KA, Kern KB. Аcute ischemic syndromes. Adjunctive Therapy. Cardiology Clinics 2002; 20(1): 159-75.Littrell KA, Kern KB. Аcute ischemic syndromes. Adjunctive Therapy. Cardiology Clinics 2002; 20(1): 159-75.Преображенский Д.В., Сидоренко Б.А.. Острые коронарные синдромы: антиишемическая и симптоматическая терапия. Cons med 2000; 2(11): 22-8.Преображенский Д.В., Сидоренко Б.А.. Острые коронарные синдромы: антиишемическая и симптоматическая терапия. Cons med 2000; 2(11): 22-8.Jugdutt BI. Effect of nitrates on myocardial remodeling after acute myocardial infarction. Am J Cardiol 1996; 77(13): 17C-23.Jugdutt BI. Effect of nitrates on myocardial remodeling after acute myocardial infarction. Am J Cardiol 1996; 77(13): 17C-23.ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction—executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. JACC 2004; 44: 671-719.ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction—executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. JACC 2004; 44: 671-719.Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-52.Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-52.Loeb HS, Johnson G, Henrick A, et al, for the V-HeFT VA Cooperative Studies Group. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. Circulation 1993; 87: VI78-87.Loeb HS, Johnson G, Henrick A, et al, for the V-HeFT VA Cooperative Studies Group. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. Circulation 1993; 87: VI78-87.Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112; 154-235.ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112; 154-235.Scholze J. The spectrum of extracardial, clinical indications for nitroglycerin and nitrates. Nitroglycerin 8: basics, standard and elective applications / Eight Hamburg Symposium. Ed. H.C. Mehmel. – Berlin; New York: de Gruyter, 1996; 97-114.Scholze J. The spectrum of extracardial, clinical indications for nitroglycerin and nitrates. Nitroglycerin 8: basics, standard and elective applications / Eight Hamburg Symposium. Ed. H.C. Mehmel. – Berlin; New York: de Gruyter, 1996; 97-114.Tucker A.T., Pearson R.M., Cooke E.D., Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet 1999; 354(9191): 1670-5.Tucker A.T., Pearson R.M., Cooke E.D., Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud’s syndrome: a randomised trial. Lancet 1999; 354(9191): 1670-5.Елисеева Т.О., Бишеле Н.А. Применение вазоактивных препаратов для лечения ишемических заболеваний зрительного нерва и сетчатки. РМЖ 2000; 8(1): 16-8.Елисеева Т.О., Бишеле Н.А. Применение вазоактивных препаратов для лечения ишемических заболеваний зрительного нерва и сетчатки. РМЖ 2000; 8(1): 16-8.Piscaglia F, Gaiani S, Siringo S, et al. Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5-mononitrate on portal flow and splanchnic arterial circulation in cirrhosis. Aliment Pharmacol Ther 1998; 12(5): 475-81.Piscaglia F, Gaiani S, Siringo S, et al. Duplex-Doppler evaluation of the effects of propranolol and isosorbide-5-mononitrate on portal flow and splanchnic arterial circulation in cirrhosis. Aliment Pharmacol Ther 1998; 12(5): 475-81.Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31(6): 1239-45.Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000; 31(6): 1239-45.Garcia4Pagan JC, Villanueva C, Vila MC, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001; 121(4): 908-14.Garcia4Pagan JC, Villanueva C, Vila MC, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology 2001; 121(4): 908-14.Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345(9): 647-55.Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345(9): 647-55.Воробьева Г.И., Щелыгин Ю.А., Благодарный Л.А. Фармакотерапия геморроя: алгоритм выбора препарата. Cons med 2001; 3(11): 17-24.Воробьева Г.И., Щелыгин Ю.А., Благодарный Л.А. Фармакотерапия геморроя: алгоритм выбора препарата. Cons med 2001; 3(11): 17-24.Thomson AJ, Lunan CB, Cameron AD, et al. Nitric oxide donors induce ripening of the human uterine cervix: a randomised controlled trial. Br J Obstet Gynaecol 1997; 104(9): 1054-7.Thomson AJ, Lunan CB, Cameron AD, et al. Nitric oxide donors induce ripening of the human uterine cervix: a randomised controlled trial. Br J Obstet Gynaecol 1997; 104(9): 1054-7.Дворецкий Л.И. Пожилой больной с хроническим обструктивным заболеванием легких в практике интерниста. РМЖ 1999; 7(16): 788-95.Дворецкий Л.И. Пожилой больной с хроническим обструктивным заболеванием легких в практике интерниста. РМЖ 1999; 7(16): 788-95.Задионченко В.С., Волкова Н.В., Копалова С.М. Cистемная и легочная гипертония при хронических неспецифических заболеваниях легких. РМЖ 1996; 4(12): 6-11.Задионченко В.С., Волкова Н.В., Копалова С.М. Cистемная и легочная гипертония при хронических неспецифических заболеваниях легких. РМЖ 1996; 4(12): 6-11.Ribas J, Angrill J, Barbera JA, et al. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999; 13(1): 210-2.Ribas J, Angrill J, Barbera JA, et al. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999; 13(1): 210-2.Yuen KCJ, Baker NR, Rayman G. Treatment of Chronic Painful Diabetic Neuropathy With Isosorbide Dinitrate Spray. Diabetes Care 2002; 25: 1699-703.Yuen KCJ, Baker NR, Rayman G. Treatment of Chronic Painful Diabetic Neuropathy With Isosorbide Dinitrate Spray. Diabetes Care 2002; 25: 1699-703.Bertrand ME, Simoons, Fox KAA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21(17): 1506-32.Bertrand ME, Simoons, Fox KAA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21(17): 1506-32.Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Effects of enalapril during continuous nitrate therapy: analysis of diameter of coronary arteries and platelet cyclic guanosine monophosphate. Am Heart J 1997; 134(4): 614-21.Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Effects of enalapril during continuous nitrate therapy: analysis of diameter of coronary arteries and platelet cyclic guanosine monophosphate. Am Heart J 1997; 134(4): 614-21.Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. JACC 1998; 31(1): 83-8.Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. JACC 1998; 31(1): 83-8.Panesar NS, Chan KW. Decreased steroid hormone synthesis from inorganic nitrite and nitrate: studies in vitro and in vivo. Toxicol Appl Pharmacol 2000; 169(3): 222-30.Panesar NS, Chan KW. Decreased steroid hormone synthesis from inorganic nitrite and nitrate: studies in vitro and in vivo. Toxicol Appl Pharmacol 2000; 169(3): 222-30.Abshagen U. Controlled clinical studies of tolerance development and dosing problems in nitrate therapy. Herz 1996; 21(Suppl 1): 23-30.Abshagen U. Controlled clinical studies of tolerance development and dosing problems in nitrate therapy. Herz 1996; 21(Suppl 1): 23-30.Ishikawa K, Yamamoto T, Kanamasa K, et al. Intermittent nitrate therapy for prior myocardial infaraction does not induce rebound angina nor reduce cardiac events. Intern Med 2000; 39(12): 1020-6.Ishikawa K, Yamamoto T, Kanamasa K, et al. Intermittent nitrate therapy for prior myocardial infaraction does not induce rebound angina nor reduce cardiac events. Intern Med 2000; 39(12): 1020-6.Kosmicki M, Sadowski Z, Szwed H, Kowalik I. What intervals in oral therapy of isosorbide dinitrate in various doses are sufficient to prevent nitrate tolerance? Med Sci Monit 2000; 6(4): 763-8.Kosmicki M, Sadowski Z, Szwed H, Kowalik I. What intervals in oral therapy of isosorbide dinitrate in various doses are sufficient to prevent nitrate tolerance? Med Sci Monit 2000; 6(4): 763-8.Аронов Д.М., Лупанов В.П. Актуальные вопросы лечения больных статбильной стенокардией. Врач 2005; 9: 3-7.Аронов Д.М., Лупанов В.П. Актуальные вопросы лечения больных статбильной стенокардией. Врач 2005; 9: 3-7.

The authors declare that there are no conflicts of interest present.